1 / 1

Kobayakawa S. : cova@med.toho-u.ac.jp

PEA+Silicone IOL. E. faecalis (10 6 CFU/eye). rabbit. GFLX. MFLX. 8.00. 8.00. 6.00. 6.00. log CFU/ml. 4.00. 4.00. 2.00. 2.00. 24h. 48h. 72h. 24h. 48h. 72h.

elvin
Download Presentation

Kobayakawa S. : cova@med.toho-u.ac.jp

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PEA+Silicone IOL E. faecalis (106 CFU/eye) rabbit GFLX MFLX 8.00 8.00 6.00 6.00 log CFU/ml 4.00 4.00 2.00 2.00 24h 48h 72h 24h 48h 72h The fourth generation quinolone eyedrops could not prevent from endophthalmitis in a rabbit modelKobayakawa S, Watanabe H, Tsuji A, Tochikubo T.(Toho University, Tokyo, Japan) Methods: Administraion of 0.5%MFLX & 0.3%GFLX (x8, every 15min.). Starting @ 4h and 6h postoperatively. Purpose: To evaluate the in vivo efficacy of gatifloxacin 0.3% and moxifloxacin 0.5% eyedrops in the treatment of Enterococcus faecalis endophthalmitis in a rabbit model. Enucleation of the surgical eye @ 24hr, 48hr and 72hr postoperatively. Examination for the bacterial population. Results: Starting @ 4h postoperatively Starting @ 6h postoperatively No significant differences in those two eyedrops treatment groups Conclusion: We previously reported that a multiple-drop schedule of gatifloxacin produced high aqueous concentrations in a rabbit model. However, multiple administrations for the fourth generation quinolone eyedrops were not efficacy for E. faecalis endophthalmitis in a rabbit model. Kobayakawa S. : cova@med.toho-u.ac.jp

More Related